Substrate activity at CYP3A5 in human liver microsomes assessed as enzyme-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation preincubated for 3 mins followed by NADPH addition measured after 20 mins by UFLC-DAD analysis
Substrate activity at CYP3A5 in human liver microsomes assessed as enzyme-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation in presence of S-adenosyl-L-methionine by UFLC-DAD analysis
Substrate activity at CYP3A5 in human liver microsomes assessed as enzyme-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation in presence of UDP-glucuronic acid by UFLC-DAD analysis
Substrate activity at CYP3A5 in human liver microsomes assessed as enzyme-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation in presence of 3'-phosphoadenosine-5'-phosphosulfate by UFLC-DAD analysis
Substrate activity at recombinant human CYP3A4 expressed in bactosomes assessed as enzyme-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP3A5 expressed in bactosomes assessed as CYP3A5-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at CYP2A6 in human liver microsomes with NADPH-generating system assessed as CYP2A6-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 uM after 25 mins in presence of 8-methoxypsoralen
Substrate activity at recombinant human CYP1A1 expressed in bactosomes assessed as CYP1A1-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP1A2 expressed in bactosomes assessed as CYP1A2-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP1B1 expressed in bactosomes assessed as CYP1B1-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2A6 expressed in bactosomes assessed as CYP2A6-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2B6 expressed in bactosomes assessed as CYP2B6-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2C8 expressed in bactosomes assessed as CYP2C8-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2C9 expressed in bactosomes assessed as CYP2C9-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2C19 expressed in bactosomes assessed as CYP2C19-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2D6 expressed in bactosomes assessed as CYP2D6-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2E1 expressed in bactosomes assessed as CYP2E1-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis
Substrate activity at recombinant human CYP2J2 expressed in bactosomes assessed as CYP2J2-mediated benzoic acid (6R,7S)-2,6,10-trihydroxy-1,3,11,12-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-dibenzo[a,c]cycloocten-5-yl ester formation at 5 to 50 uM after 30 mins in presence of NADPH by UFLC-DAD analysis